How does rare disease prevalence impact drug pricing in England?
This article was originally published in PharmaPhorum. In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice...
Eva Marchese specializes in competitive strategy, pricing, market access, and research primarily in the pharmaceutical, biotech, and life sciences industries. She has an extensive consulting background with a focus on advising pharmaceutical, medical device companies, and medical technology (MedTech) companies on global pricing and market access. Dr. Marchese has expertise in multiple therapy areas, including oncology, immunology, biosimilars, vaccines, and tendering.
Prior to joining CRA, Dr. Marchese was Senior Principal, Pricing & Market Access at QuintilesIMS, now doing business as IQVIA, with a focus on pricing, market access, regulatory, funding, and tendering. As a Partner at Sanità & Management Consulting, Eva was involved in several ministerial committees at the Italian Ministry of Health, examining cost evaluations and analyzing healthcare organizations’ procedures. She was previously Professor of Public Management and Policy at Bocconi-SDA and a contracted Research Fellow at the Center for Research on Healthcare and Social Management at Bocconi University.
Dr. Marchese frequently presents at industry conferences and has written articles for various publications. She speaks Italian and English and is advanced in Spanish.